Drug Interaction:
Antineuoplastic agents include-
Interferon ALFA 2a, Interferon ALFA -2b, Interferon ALFA -n3, Levamisole, Altretamine, Cladribine, Hydroxyurea, Aldesleukin, Paclitaxel, Docetaxel,Tretinion, Procarbazine,Dacarbazine, Gemcitabine, Mitotane, Asparaginase, Pegaspargase,Porfimer Sodium
Drug Interactions- summary
+ Aldesleukin-
Antihypertensives +
Antihypertensives potentiate the hypotension seen with aldesleukin.
Corticosteroids +
Concomittant use reduce the antitumor effectiveness of aldesleukin,
avoid concurrent use
Cardiotoxic agent eg. Doxorubicin / Hepatotoxic agent eg. methotrexate/
Myelotoxic agents eg. cytotoxic chemot /Nephrotoxic agents eg. indomethicin +
Increased toxicity in these organ system occur with concomitant administration
Aldesleukin + Psychotropic agents
Aldesleukin affect CNS function. Therefore, interactions occur following concurrent use
Indication:
Approved by FDA on May 5, 1992
Indication
Metastatic renal cell carcinoma
Dosage:
Administer by a 15 minute IV infusion every 8 hrs.
Metastatic renal cell carcinoma
Antineuoplastic agents include-
Interferon ALFA 2a, Interferon ALFA -2b, Interferon ALFA -n3, Levamisole, Altretamine, Cladribine, Hydroxyurea, Aldesleukin, Paclitaxel, Docetaxel,Tretinion, Procarbazine,Dacarbazine, Gemcitabine, Mitotane, Asparaginase, Pegaspargase,Porfimer Sodium
Adverse Reaction:
Hypotension, Sinus tachycardia,
Supraventricular tachycardia, Bradycardia,
Pulmonary congestion, Dyspnea,
Pulmonary edema, Respiratory failure,
Jaundice, Ascites, Anemia,
Thrombocytopenia, Coagulation disorders.
Elevated bilirubin, Elevated transaminase.
Contra-Indications:
Hypersens to the drug
Special precautions:
Monitoring- hematological tests. Anemia /thrombocytopenia may occur.
Changes in mental status
Thyroid function impairment.
Dosages/ Overdosage Etc:
Indication
Metastatic renal cell carcinoma
Dosage:
Administer by a 15 minute IV infusion every 8 hrs.
Patient Information:
Ref- Advice for the Patient - Drug Information in Lay Language- USPDI (1997)
Aldesleukin - Systemic
1.Allergies-
Tell your doctor if you have ever had any unusual oe allergic reaction to aldesulekin
2.Pregnancy-
Aldesleukin has not been studied humans or in animals. However, because this
may medicine cause serious side side effects , use during pregnancy is usually
not recommended.
3.Breast -feeding-
It is not known whether aldeslukin passes into breast milk.
4.Children-
No specific information comparing use of aldesleukin in children with use in other
age groups.
5.Elderly-
Many medicines have not been studied specifically in older people. Therefore
it may not be known whether they work excactly the same way they do in younger
adults. There is no specific information comparing use of aldeslukin in the elderly
with use in other age groups.
6.Other medicines -
Although certain medicines should not be used together at all, in other cases two
different medicines may be used together even if an interaction might occur. in such
cases your doctor may want to change the dose, or other precautions may be necessary.
Tell your health care professional if you are taking any other medicines.
7.Other medical problems-
The presence of other medical problems may affect the use of aldesleukin. Make sure that you tell your doctor if you have any other medical problems especially-
Chickenpox (including recent exposure) or
Herpes zoster (shingles) - risk of severe disease affecting other parts of the body
Heart disease or
Immune system problems or
Liver disease or
Lung disease or
Psoriasis or
Ulcerative thyrod- may be worsened by aldesleukin
Infection - aldesleukin decrease your bodys ability to fight infection
Kidney disease- efects of aldesleukin may be increased because of slower removal
from the body
Mental problems- aldesleukin may make them worse
Seizures- (hisory of ) aldesleukin can cause seizures
Pharmacology/ Pharmacokinetics:
Pharmacology:
Aldesleukin, a human recombinant interleukin-2 product, is a highly purifed (lymphokine) produced by recombinant DNA technology using a genetically engineered E. Coli strain, containing an analog of the human interleukin-2 gene.
Pharmacokinetics:
Following the initial rapid organ distribution the primary route of clearance of circulating aldeslekin is the kidney. The mean clearance rate in cancer patients is 268ml/min.
Pregnancy and lactation:
Pregnancy:
Only give to a pregnant woman with extreme caution
Lactation:
Excercise caution and decide whether to discontinue the drug or discontinue nursing depending on the importance of the drug to the mother.
Manufacturer Details